相关实验视频
Updated: May 30, 2025

05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
89
关于阿尔茨海默氏症连续体中的生物标志物的新研究
Immacolata Vecchio1, Carmela Colica2
1CNR-IRIB, Secondary Site, Azienda Ospedaliero-Universitaria “Renato Dulbecco” Catanzaro, Italy
Reviews on recent clinical trials
|January 27, 2025
概括
对阿尔茨海默病 (AD) 的早期诊断至关重要. 识别特定的生物标志物允许在显著的神经退行发生之前及时使用疾病修饰疗法 (DMT) 干预.
科学领域:
- 神经科学是一个神经科学.
- 病理学 病理学 病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,影响超过60%的患者.
- 了解AD的分子基础使得开发新疗法成为可能.
- 目前的治疗方法包括症状抗胆酶 (AChEs) 和新兴的疾病修饰疗法 (DMT).
研究的目的:
- 审查用于早期发现阿尔茨海默病的特定生物标志物.
- 突出早期诊断对于有效的治疗策略的重要性.
- 探索治疗临床前阿尔茨海默病和阻止进展的新方法.
主要方法:
- 对有关阿尔茨海默病生物标志物的现有文献的审查.
- 基于疾病阶段的治疗疗效的分析.
- 讨论生物标志物的诊断和预后影响.
主要成果:
- 症状疗法 (AChEs) 在轻度至中度的AD中最有效.
- 针对粉样β (Aβ) 和 (τ) 的疾病修饰疗法 (DMT) 在临床前阶段更有效.
- 生物标志物对于早期发现AD,预测痴呆风险和监测疾病进展至关重要.
结论:
- 通过生物标志物早期识别AD对于有效治疗至关重要.
- 用DMT针对临床前的AD提供了一个有希望的策略来减缓疾病的进展.
- 需要对新的生物标志物和治疗途径进行持续的研究,以对抗AD.
更多相关视频
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
756
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.8K
相关概念视频
Alzheimer's Disease: Overview
439
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
439
Alzheimer's Disease: Treatment
160
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
160
Dementia
92
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
92